The National Center for Health Research and 24 other organizations have expressed concern over Dr. Nancy Beck’s appointment to a senior position at the EPA, highlighting her previous role at the American Chemistry Council and potential conflicts of interest that could influence the agency’s chemical safety policies.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
NCHR Comment on the USPSTF’s Draft Recommendations for Prostate Cancer Screening
May 8, 2017. We support the efforts of the U.S. Preventive Services Task Force (USPSTF) to re-evaluate its recommendations in light of new research regarding prostate cancer screening that provides new insights into its benefits and risks.
Read More »NCHR Testimony to the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria on Animal Antibiotics
May 4, 2017. We support efforts by federal agencies to reduce unnecessary exposures to antibiotics. Reducing unnecessary exposure reduces antibiotic resistance, and thus preserves the use of these antibiotics for animal and human health.
Read More »NCHR Comment on the USPSTF’s Draft Recommendations for Breast Cancer: Medications for Risk Reduction
April 19, 2017. We support the USPSTF’s efforts to re-evaluate recommendations as the scientific evidence expands and improves. In addition, we strongly urge the USPSTF to consider how the apparently modest benefits of medications compare to specific lifestyle changes for reducing breast cancer risk.
Read More »NCHR Comment on the USPSTF’s Draft Recommendations for BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic Testing
April 12, 2017. We support the USPSTF’s efforts to provide updated recommendations on risk assessment, genetic counseling, and genetic testing on BRCA-related cancer, based on quality, up-to-date scientific studies. We hope the review will quantify the benefits and harms of each step starting with screening, in order to help USPSTF to make meaningful recommendations for appropriate subpopulations of women.
Read More »